| Chen, Ying |
NCT06496048: Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC |
|
|
| Recruiting | 3 | 180 | RoW | Lurbinectedin, PM01183, Irinotecan, Topotecan | Luye Pharma Group Ltd. | Relapsed Small Cell Lung Cancer | 12/27 | 06/28 | | |
NCT04547049: A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies |
|
|
| Recruiting | 3 | 160 | RoW | Cytarabine, Busulfan, Cyclophosphamide, Me-CCNU, Rabbit antithymocyte globulin, Allogeneic HSCT, Cyclosporin A, Mycophenolate Mofetil, MTX | First Affiliated Hospital of Zhejiang University | Leukemia | 09/25 | 12/25 | | |
NCT05844150: A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC |
|
|
| Recruiting | 2/3 | 445 | RoW | PM8002, Platinum, Atezolizumab, Etoposide | Biotheus Inc. | SCLC | 06/25 | 12/25 | | |
NCT05466149: Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 Insertion |
|
|
| Recruiting | 2 | 100 | RoW | Furmonertinib, AST2818 | Allist Pharmaceuticals, Inc. | NSCLC | 04/24 | 08/26 | | |
| Recruiting | 2 | 30 | RoW | Neoadjuvant Chemotherapy in Combination with Toripalimab, HR+ HER2 breast cancer | First Affiliated Hospital of Zhejiang University | HR+/HER2- Breast Cancer | 06/26 | 06/29 | | |
NCT06623136: A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer |
|
|
| Not yet recruiting | 2 | 40 | RoW | ES102, Toripalimab | Elpiscience (Suzhou) Biopharma, Ltd. | Non-Small Cell Lung Cancer | 02/27 | 12/27 | | |
| Recruiting | 2 | 35 | RoW | Neoadjuvant chemotherapy combined with Toripalimab | First Affiliated Hospital of Zhejiang University | TNBC, Triple Negative Breast Cancer | 10/26 | 10/29 | | |
NCT06727617: Serplulimab With Chemoradiotherapy for Postoperative Cervical Cancer With Risk Factors |
|
|
| Recruiting | 2 | 134 | RoW | Serplulimab, Chemotherapy, radiotherapy | Tianjin Medical University Cancer Institute and Hospital | Cervical Cancers | 12/25 | 12/26 | | |
NCT05627063: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 169 | US, RoW | ABSK121-NX | Abbisko Therapeutics Co, Ltd | Solid Tumor | 03/25 | 06/25 | | |
NCT05244551: A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 85 | US, RoW | ABSK061 | Abbisko Therapeutics Co, Ltd | Solid Tumor | 04/25 | 04/25 | | |
NCT05501912: A Study of ABM-1310 in Patients With BRAF V600-Mutant Advanced Solid Tumors |
|
|
| Terminated | 1 | 20 | RoW | ABM-1310 | ABM Therapeutics Shanghai Company Limited | Advanced Solid Tumor, BRAF V600 Mutation | 06/24 | 06/24 | | |
| Completed | N/A | 149 | RoW | iNCDSS based insulin regime, routine insulin treatment regime | Shanghai Zhongshan Hospital, Shanghai Fifth People's Hospital,Fudan University, XuHui Central Hospital of Shanghai, Shanghai, China | Type 2 Diabetes | 09/22 | 09/22 | | |
NCT05026229: A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL |
|
|
| Recruiting | N/A | 60 | RoW | dasatinib plus consolidation chemotherapy with vincristine and prednisone, Dasatinib + VP Regimen, dasatinib plus consolidation chemotherapy with high-dose methotrexate and cytarabine, Dasatinib + HyperB Regimen | First Affiliated Hospital Xi'an Jiaotong University | Precursor Cell Lymphoblastic Leukemia-Lymphoma, Philadelphia-Positive Acute Lymphoblastic Leukemia, ALL, Adult | 06/23 | 06/23 | | |
NCT05024357: A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL |
|
|
| Recruiting | N/A | 80 | RoW | Dasatinib, Dasatinib tablet | First Affiliated Hospital Xi'an Jiaotong University | Precursor Cell Lymphoblastic Leukemia-Lymphoma, Philadelphia-Positive Acute Lymphoblastic Leukemia, ALL, Adult | 06/23 | 06/23 | | |
NCT05814172: ADL and CONUT for Predicting 1-year Mortality Risk in Older Adults After Hip Fracture |
|
|
| Recruiting | N/A | 303 | RoW | no intervention | Beijing Tongren Hospital | All-cause Mortality | 11/23 | 11/23 | | |
| Recruiting | N/A | 200 | US | Lumbar Interbody Fusion | 3Spine, MCRA | Lumbar Spine Degeneration | 05/24 | 08/26 | | |
NCT04350060: Improving the Quality of Dementia Care Through Innovative Redesign of the Memory Care Environment |
|
|
| Recruiting | N/A | 20 | US | Retro-fitted room with technological enhancements | Mayo Clinic | Dementia | 12/25 | 03/26 | | |
NCT05355675: The Association of Microbiota Composition With cGVHD After Allo-HSCT |
|
|
| Recruiting | N/A | 300 | RoW | blood sample, stool sample | First Affiliated Hospital of Zhejiang University | Hematopoietic Stem Cell Transplantation, Hematologic Malignancy, Chronic Graft-versus-host-disease, Complication | 05/25 | 05/25 | | |
| Recruiting | N/A | 366 | RoW | Cardiopulmonary rehabilitation, Usual care | The First Affiliated Hospital with Nanjing Medical University | Critical Illness | 06/25 | 12/25 | | |
NCT05375786: Epidemiological Study on Asymptomatic Infections and Mild Illness With Covid-19 in Shanghai |
|
|
| Recruiting | N/A | 10000 | RoW | Vaccination completion status | Ruijin Hospital | COVID-19 | 06/22 | 07/22 | | |
NCT05387304: A Follow-up Study of Asymptomatic Infections and Diagnosed Patients With Covid-19 in Shanghai |
|
|
| Recruiting | N/A | 250000 | RoW | | Ruijin Hospital | COVID-19 | 05/32 | 05/32 | | |
